Key Metrics
CiteScore 

0.1
Recommended pre-submission checks
Powered by 

Archivos de prevención de riesgos laborales Journal Specifications
Indexed in the following public directories
DOAJ
| Overview | |
| Publisher | Societat Catalana de Seguretat i Medicina del Treball (SCSMT) |
| Language | Spanish,Catalan |
| Publication Time | 20 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | Spanish,Catalan |
| Website URL | Visit website |
| Publication Details | |
| Publication Time | 20 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Dulcinea |
| License type | CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Archivos de prevención de riesgos laborales ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Archivos de prevención de riesgos laborales
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab+bevacizumab+stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
- 16 Apr 2027
- Lung cancer (Amsterdam, Netherlands)
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy
- 1 Jul 2026
- Lung Cancer
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab+bevacizumab+stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
- 16 Apr 2027
- Lung cancer (Amsterdam, Netherlands)
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy
- 1 Jul 2026
- Lung Cancer
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
- 1 Jun 2026
- Lung cancer (Amsterdam, Netherlands)